Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

MLA

Kantarjian, Hagop M., et al. “Phase 1/2 Study of DFP-10917 Administered by Continuous Intravenous Infusion in Patients with Recurrent or Refractory Acute Myeloid Leukemia.” Cancer (0008543X), vol. 125, no. 10, May 2019, pp. 1665–73. EBSCOhost, https://doi.org/10.1002/cncr.31923.

APA

Kantarjian, H. M., Jabbour, E. J., Garcia, M. G., Kadia, T. M., DiNardo, C. D., Daver, N. G., Borthakur, G., Jain, N., Waukau, J. B., Kwari, M. I., Ravandi, F., Anderson, B. D., Iizuka, K., Jin, C., Zhang, C., Plunkett, W. K., & Garcia-Manero, G. (2019). Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer (0008543X), 125(10), 1665–1673. https://doi.org/10.1002/cncr.31923

Chicago

Kantarjian, Hagop M., Elias J. Jabbour, Manero, Guillermo Garcia, Tapan M. Kadia, Courtney D. DiNardo, Naval G. Daver, Gautam Borthakur, et al. 2019. “Phase 1/2 Study of DFP-10917 Administered by Continuous Intravenous Infusion in Patients with Recurrent or Refractory Acute Myeloid Leukemia.” Cancer (0008543X) 125 (10): 1665–73. doi:10.1002/cncr.31923.